The ICH E14 clinical guidance was revised in December 2015. It now enables the use of exposure response (ER) analysis applied to early phase clinical data to provide definitive evidence of the lack of a QT effect of a drug in development.
A simulation study was conducted to evaluate performance of different ER analyses using concentration QTc data and make recommendations on appropriate ER analyses.
|